Combining TIGIT blockage with MDSC inhibition hinders breast cancer bone metastasis by activating anti-tumor immunity
Bone is the most common site of breast cancer metastasis. Bone metastasis are incurable and are associated with severe morbidity. Utilizing an immunocompetent mouse model of spontaneous breast cancer bone metastasis, we profiled the immune transcriptome of bone metastatic lesions and peripheral bone marrow at distinct metastatic stages, revealing dynamic changes during the metastatic process. We show that crosstalk between granulocytes and T cells is central to shaping an immunosuppressive microenvironment. Specifically, we identified the PD-1 and TIGIT signaling axes and the pro-inflammatory cytokine IL1b as central players in the interactions between granulocytes and T cells. Targeting these pathways in vivo resulted in attenuated bone metastasis and improved survival, by reactivating anti-tumor immunity. Analysis of patient samples revealed that TIGIT and IL1b are prominent in human bone metastasis. Our findings suggest that co-targeting immunosuppressive granulocytes and dysfunctional T cells may be a promising novel therapeutic strategy to inhibit bone metastasis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Cancer discovery - (2024) vom: 01. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Monteran, Lea [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 01.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1158/2159-8290.CD-23-0762 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369174410 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369174410 | ||
| 003 | DE-627 | ||
| 005 | 20240302232752.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240302s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/2159-8290.CD-23-0762 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1314.xml |
| 035 | |a (DE-627)NLM369174410 | ||
| 035 | |a (NLM)38427556 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Monteran, Lea |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Combining TIGIT blockage with MDSC inhibition hinders breast cancer bone metastasis by activating anti-tumor immunity |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Bone is the most common site of breast cancer metastasis. Bone metastasis are incurable and are associated with severe morbidity. Utilizing an immunocompetent mouse model of spontaneous breast cancer bone metastasis, we profiled the immune transcriptome of bone metastatic lesions and peripheral bone marrow at distinct metastatic stages, revealing dynamic changes during the metastatic process. We show that crosstalk between granulocytes and T cells is central to shaping an immunosuppressive microenvironment. Specifically, we identified the PD-1 and TIGIT signaling axes and the pro-inflammatory cytokine IL1b as central players in the interactions between granulocytes and T cells. Targeting these pathways in vivo resulted in attenuated bone metastasis and improved survival, by reactivating anti-tumor immunity. Analysis of patient samples revealed that TIGIT and IL1b are prominent in human bone metastasis. Our findings suggest that co-targeting immunosuppressive granulocytes and dysfunctional T cells may be a promising novel therapeutic strategy to inhibit bone metastasis | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Ershaid, Nour |e verfasserin |4 aut | |
| 700 | 1 | |a Scharff, Ye'ela |e verfasserin |4 aut | |
| 700 | 1 | |a Zoabi, Yazeed |e verfasserin |4 aut | |
| 700 | 1 | |a Sanalla, Tamer |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Yunfeng |e verfasserin |4 aut | |
| 700 | 1 | |a Pavlovsky, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Zait, Yael |e verfasserin |4 aut | |
| 700 | 1 | |a Langer, Marva |e verfasserin |4 aut | |
| 700 | 1 | |a Caller, Tal |e verfasserin |4 aut | |
| 700 | 1 | |a Eldar-Boock, Anat |e verfasserin |4 aut | |
| 700 | 1 | |a Avivi, Camila |e verfasserin |4 aut | |
| 700 | 1 | |a Sonnenblick, Amir |e verfasserin |4 aut | |
| 700 | 1 | |a Satchi-Fainaro, Ronit |e verfasserin |4 aut | |
| 700 | 1 | |a Barshack, Iris |e verfasserin |4 aut | |
| 700 | 1 | |a Shomron, Noam |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xiang H-F |e verfasserin |4 aut | |
| 700 | 1 | |a Erez, Neta |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer discovery |d 2011 |g (2024) vom: 01. März |w (DE-627)NLM215937023 |x 2159-8290 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:01 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/2159-8290.CD-23-0762 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 01 |c 03 | ||